FlowMedica Overview
- Year Founded
-
2002
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.75M
FlowMedica General Information
Description
Developer of commercial-stage medical devices designed to offer targeted renal therapy for renal conditions associated with cardiovascular disease, cancer and surgery. The company's devices serve as an alternative to the standard delivery method of systemic intravenous (IV) infusion to address kidney dysfunction related to a number of conditions, including cardiovascular, endovascular, and surgical procedures and diseases, enabling surgeons to perform the infusion directly and with a careful measure.
Contact Information
Website
www.flowmedica.comCorporate Office
- 46563 Fremont Boulevard
- Fremont, CA 94538
- United States
Corporate Office
- 46563 Fremont Boulevard
- Fremont, CA 94538
- United States
FlowMedica Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 12-Jan-2009 | $1.75M | Completed | Generating Revenue | ||
| 4. Later Stage VC (Series D) | 15-Nov-2005 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series C) | 19-Aug-2004 | Completed | Startup | |||
| 2. Early Stage VC (Series B) | Completed | Startup | ||||
| 1. Early Stage VC (Series A) | Completed | Startup |
FlowMedica Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B2 | ||||||||
| Series B1 | ||||||||
| Series A2 | 1,411,764 | $0.001000 | $1 | $1 | 1x | $1 | 3.27% | |
| Series A1 | 3,000,000 | $0.001000 | $1 | $1 | 1x | $1 | 6.95% |
FlowMedica Patents
FlowMedica Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20090105799-A1 | Renal assessment systems and methods | Inactive | 23-Oct-2007 | ||
| WO-2009055564-A1 | Renal assessment systems and methods | Inactive | 23-Oct-2007 | ||
| WO-2008112563-A1 | Acute kidney injury treatment systems and methods | Inactive | 09-Mar-2007 | ||
| EP-2023997-A2 | Selective renal cannulation and infusion systems and methods | Inactive | 08-Jun-2006 | ||
| EP-2023997-A4 | Selective renal cannulation and infusion systems and methods | Inactive | 08-Jun-2006 | A61M25/0068 |
FlowMedica Former Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ABN AMRO Bank | Investment Bank | Minority | ||
| De Novo Ventures | Venture Capital | Minority | ||
| Forbion | Venture Capital | Minority | ||
| Medica Venture Partners | Venture Capital | Minority | ||
| Mi3 Venture Partners | Venture Capital | Minority |
FlowMedica FAQs
-
When was FlowMedica founded?
FlowMedica was founded in 2002.
-
Where is FlowMedica headquartered?
FlowMedica is headquartered in Fremont, CA.
-
What industry is FlowMedica in?
FlowMedica’s primary industry is Other Devices and Supplies.
-
Is FlowMedica a private or public company?
FlowMedica is a Private company.
-
What is the current valuation of FlowMedica?
The current valuation of FlowMedica is .
-
What is FlowMedica’s current revenue?
The current revenue for FlowMedica is .
-
How much funding has FlowMedica raised over time?
FlowMedica has raised $20.6M.
-
Who are FlowMedica’s investors?
ABN AMRO Bank, De Novo Ventures, Forbion, Medica Venture Partners, and Mi3 Venture Partners are 5 of 9 investors who have invested in FlowMedica.
-
When was FlowMedica acquired?
FlowMedica was acquired on 12-Jan-2009.
-
Who acquired FlowMedica?
FlowMedica was acquired by Angiodynamics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process